FGR: Falk Foundation

Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Aminotransferases during treatment predict long-term survival in patients with autoimmune hepatitis type 1: A landmark analysis

Clin Gastroenterol Hepatol. 2022;20(8):1776–83.e4

A phase 2, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

J Hepatol. 2022;77(2):353–64

Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

J Hepatol. 2022;77(1):84–97

Montano-Loza AJ, Ronca V, Ebadi M, Hansen BE, Hirschfield G, Elwir S, Alsaed M, Milkiewicz P, Janik MK, Marschall HU, Burza MA, Efe C, Calışkan AR, Harputluoglu M, Kabaçam G, Terrabuio D, de Quadros Onofrio F, Selzner N, Bonder A, Parés A, Llovet L, Akyıldız M, Arikan C, Manns MP, Taubert R, Weber AL, Schiano TD, Haydel B, Czubkowski P, Socha P, Ołdak N, Akamatsu N, Tanaka A, Levy C, Martin EF, Goel A, Sedki M, Jankowska I, Ikegami T, Rodriguez M, Sterneck M, Weiler-Normann C, Schramm C, Donato MF, Lohse A, Andrade RJ, Patwardhan VR, van Hoek B, Biewenga M, Kremer AE, Ueda Y, Deneau M, Pedersen M, Mayo MJ, Floreani A, Burra P, Secchi MF, Terziroli Beretta-Piccoli B, Sciveres M, Maggiore G, Jafri SM, Debray D, Girard M, Lacaille F, Lytvyak E, Mason AL, Heneghan M, Oo YH; International Autoimmune Hepatitis Group (IAIHG)

A revised electronic version of RUCAM for the diagnosis of DILI

Hepatology. 2022;76(1):18–31

Germline mutations in CIDEB and protection against liver disease

N Engl J Med. 2022;387(4):332–44

Verweij N, Haas ME, Nielsen JB, Sosina OA, Kim M, Akbari P, De T, Hindy G, Bovijn J, Persaud T, Miloscio L, Germino M, Panagis L, Watanabe K, Mbatchou J, Jones M, LeBlanc M, Balasubramanian S, Lammert C, Enhörning S, Melander O, Carey DJ, Still CD, Mirshahi T, Rader DJ, Parasoglou P, Walls JR, Overton JD, Reid JG, Economides A, Cantor MN, Zambrowicz B, Murphy AJ, Abecasis GR, Ferreira MAR, Smagris E, Gusarova V, Sleeman M, Yancopoulos GD, Marchini J, Kang HM, Karalis K, Shuldiner AR, Della Gatta G, Locke AE, Baras A, Lotta LA

Fazirsiran for liver disease associated with alpha-1-antitrypsin deficiency

N Engl J Med. 2022;387(6):514–24

The association between proton-pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: A Veterans Affairs Cohort Study

Gastroenterology. 2022;163(1):257–69.e6

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

J Hepatol. 2022;77(1):128–39

A randomized controlled trial comparing 20%-albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension (ALPS trial)

J Hepatol. 2022;77(3):670–82